Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has scheduled its second quarter 2025 financial results release for Monday, August 4, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results. Investors can access the webcast through the company's website or direct link, with U.S. participants able to join via phone at 1-833-470-1428 using access code 638217. A Q&A session will follow management's presentation, and a replay will be available after the call.
Castle Biosciences (Nasdaq: CSTL), un'azienda sanitaria specializzata in test diagnostici innovativi, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per lunedì 4 agosto 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call e una webcast alle 16:30 ora orientale per discutere i risultati. Gli investitori potranno accedere alla webcast tramite il sito web dell'azienda o un link diretto, mentre i partecipanti negli Stati Uniti potranno collegarsi telefonicamente al 1-833-470-1428 utilizzando il codice di accesso 638217. Dopo la presentazione della direzione, seguirà una sessione di domande e risposte, e sarà disponibile una registrazione della chiamata.
Castle Biosciences (Nasdaq: CSTL), una empresa de salud especializada en pruebas diagnósticas innovadoras, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el lunes 4 de agosto de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. hora del Este para analizar los resultados. Los inversores podrán acceder a la transmisión a través del sitio web de la empresa o mediante un enlace directo, y los participantes en EE. UU. podrán unirse por teléfono al 1-833-470-1428 utilizando el código de acceso 638217. Después de la presentación de la gerencia, habrá una sesión de preguntas y respuestas, y estará disponible una repetición de la llamada.
Castle Biosciences (나스닥: CSTL)는 혁신적인 진단 테스트를 전문으로 하는 헬스케어 기업으로, 2025년 2분기 재무 실적 발표를 2025년 8월 4일 월요일 장 마감 후에 예정하고 있습니다.
회사는 결과 발표를 위해 동부 표준시 오후 4시 30분에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다. 투자자들은 회사 웹사이트나 직접 링크를 통해 웹캐스트에 접속할 수 있으며, 미국 참가자는 1-833-470-1428번으로 전화해 접속 코드 638217를 사용해 참여할 수 있습니다. 경영진 발표 후 질의응답 시간이 있으며, 콜 종료 후 재청취도 가능합니다.
Castle Biosciences (Nasdaq : CSTL), une entreprise de santé spécialisée dans les tests diagnostiques innovants, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le lundi 4 août 2025, après la clôture du marché.
L'entreprise organisera une conférence téléphonique et une webdiffusion à 16h30 heure de l'Est pour discuter des résultats. Les investisseurs pourront accéder à la webdiffusion via le site web de la société ou un lien direct, et les participants américains pourront se joindre par téléphone au 1-833-470-1428 en utilisant le code d'accès 638217. Une session de questions-réponses suivra la présentation de la direction, et un replay sera disponible après l'appel.
Castle Biosciences (Nasdaq: CSTL), ein Gesundheitsunternehmen, das sich auf innovative diagnostische Tests spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Montag, den 4. August 2025, nach Börsenschluss, geplant.
Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können über die Unternehmenswebsite oder einen direkten Link auf den Webcast zugreifen. Teilnehmer aus den USA können telefonisch unter 1-833-470-1428 mit dem Zugangscode 638217 teilnehmen. Nach der Präsentation der Geschäftsführung folgt eine Fragerunde, und eine Aufzeichnung wird nach dem Anruf verfügbar sein.
- None.
- None.
FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025.
Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.
To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 638217. International dial-in numbers are available here: https://www.netroadshow.com/conferencing/global-numbers?confId=84730; please use the same access code above to join the call.
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When will Castle Biosciences (CSTL) release Q2 2025 earnings?
What time is the Castle Biosciences (CSTL) Q2 2025 earnings call?
How can I access Castle Biosciences (CSTL) Q2 2025 earnings call?
Will there be a Q&A session during Castle Biosciences Q2 2025 earnings call?
